Wave Life Sciences Ltd. - Ordinary Shares (WVE)

WVE-007 obesity candidate shows 16.5% visceral fat improvement in early trials.

WAVE Life Sciences (NASDAQ:WVE) reported a wider second-quarter loss as it increased investment in its obesity and RNA-editing programs, while outlining several clinical and regulatory milestones expected in the second half of 2026. The company reported second-quarter revenue of $2.3 million, down

This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform.

Wave (WVE) Q1 2026 Earnings Call Transcript

Wave (WVE) Q2 2025 Earnings Call Transcript

Wave (WVE) Q1 2025 Earnings Call Transcript

This company's anti-obesity candidate might succeed where others are failing.

On March 26, 2026, traders mulled Wave's weak high-dose obesity results against the company's large market opportunity.

The biotechnology landscape witnessed a defining moment on March 26, 2026, as Wave Life Sciences (Nasdaq: WVE) released highly anticipated interim Phase 1 data from its INLIGHT trial. The study, which evaluates WVE-007—an investigational RNA interference (RNAi) therapy targeting the INHBE gene—aims to revolutionize obesity treatment by focusing

Wave Life Sciences (WVE) Earnings Call Transcript

This biotech innovator in genetic medicines reported significant insider selling, as disclosed in recent SEC filings.

In today's session, these stocks are experiencing unusual volume.

There's nothing like a nearly 150% price gain to garner the attention of investors and analysts.

Discover the stocks with unexpected trading volume in today's session on the US markets.

We have an emerging new entrant in the increasingly crowded weight loss drug space.